4-Methylmorpholine → (S)-4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide

HRID 2091626Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 2091626
[CH:1]1([C:4]2[N:5]=[CH:6][N:7]([C:9]3[CH:14]=[CH:13][N:12]=[C:11]([C:15]([OH:17])=O)[CH:10]=3)[CH:8]=2)[CH2:3][CH2:2]1.[F:18][C:19]([F:34])([F:33])[C@@H:20]([N:22]1[CH:26]=[N:25][N:24]=[C:23]1[C:27]1[S:28][CH:29]=[C:30]([NH2:32])[N:31]=1)[CH3:21].CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CN1CCOCC1>CN(C)C=O>[CH:1]1([C:4]2[N:5]=[CH:6][N:7]([C:9]3[CH:14]=[CH:13][N:12]=[C:11]([C:15]([NH:32][C:30]4[N:31]=[C:27]([C:23]5[N:22]([C@@H:20]([CH3:21])[C:19]([F:34])([F:33])[F:18])[CH:26]=[N:25][N:24]=5)[S:28][CH:29]=4)=[O:17])[CH:10]=3)[CH:8]=2)[CH2:2][CH2:3]1

Komponenten

6

Versuchsvorschrift

A solution of 4-(4-cyclopropyl-1H-imidazol-1-yl)picolinic acid (50 mg, 0.218 mmol), (S)-2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-amine (53 mg, 0.208 mmol), HATU (99 mg, 0.262 mmol), and N-methylmorpholine (30 μL, 0.262 mmol) in N,N-dimethylformamide (1 mL) was stirred at room temperature for 2 hours. The solvent was removed under reduced pressure, the residue was suspended in acetonitrile/water and the solids were isolated by filtration, washed with water (2 mL), acetonitrile (2 mL) and diethyl ether (5 mL) and dried under vacuum to afford (S)-4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide as a white powder (69 mg, 71% yield).

Aufarbeitung

  1. customThe solvent was removed under reduced pressure
  2. customthe solids were isolated by filtration
  3. washwashed with water (2 mL), acetonitrile (2 mL) and diethyl ether (5 mL)
  4. customdried under vacuum

Quellen und Nachweise

ORD-Eintrag
ord-095dec9fe4c94fb2b22d8bc29ae47c3e
Quelldatensatz
uspto-grants-2013_05
Patentnummer
US08440665B2

Notizen zur Reaktion

Wird geladen…